×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DNLI – denali therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DNLI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/8
08:42 am
dnli
Denali Therapeutics (NASDAQ:DNLI) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Denali Therapeutics (NASDAQ:DNLI) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
1/8
06:16 am
dnli
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up [Yahoo! Finance]
Low
Report
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up [Yahoo! Finance]
1/7
09:28 pm
dnli
Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review [Yahoo! Finance]
Medium
Report
Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review [Yahoo! Finance]
1/7
10:02 am
dnli
Denali Therapeutics (NASDAQ:DNLI) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Medium
Report
Denali Therapeutics (NASDAQ:DNLI) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
1/7
04:06 am
dnli
Denali Therapeutics (NASDAQ:DNLI) was given a new $25.00 price target on by analysts at UBS Group AG.
Medium
Report
Denali Therapeutics (NASDAQ:DNLI) was given a new $25.00 price target on by analysts at UBS Group AG.
1/6
08:00 am
dnli
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
Medium
Report
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
12/30
08:00 am
dnli
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
Low
Report
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
12/23
04:21 pm
dnli
Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions [Yahoo! Finance]
Low
Report
Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/8
04:20 pm
dnli
Form 4 Denali Therapeutics Inc. For: Jan 06 Filed by: Schuth Alexander O.
Low
Report
Form 4 Denali Therapeutics Inc. For: Jan 06 Filed by: Schuth Alexander O.
1/8
04:20 pm
dnli
Form 4 Denali Therapeutics Inc. For: Jan 06 Filed by: Watts Ryan J.
Low
Report
Form 4 Denali Therapeutics Inc. For: Jan 06 Filed by: Watts Ryan J.
1/6
08:28 pm
dnli
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
Medium
Report
Form 144 Denali Therapeutics Inc. Filed by: Ho Carole
1/6
08:25 pm
dnli
Form 144 Denali Therapeutics Inc. Filed by: Schuth Alexander O.
Medium
Report
Form 144 Denali Therapeutics Inc. Filed by: Schuth Alexander O.
1/6
08:24 pm
dnli
Form 144 Denali Therapeutics Inc. Filed by: Watts Ryan J.
Medium
Report
Form 144 Denali Therapeutics Inc. Filed by: Watts Ryan J.
1/6
08:03 am
dnli
Form 8-K Denali Therapeutics Inc. For: Jan 06
Medium
Report
Form 8-K Denali Therapeutics Inc. For: Jan 06
1/5
06:49 pm
dnli
Form 4 Denali Therapeutics Inc. For: Jan 03 Filed by: Schuth Alexander O.
Medium
Report
Form 4 Denali Therapeutics Inc. For: Jan 03 Filed by: Schuth Alexander O.
1/5
06:49 pm
dnli
Form 4 Denali Therapeutics Inc. For: Jan 03 Filed by: Watts Ryan J.
Medium
Report
Form 4 Denali Therapeutics Inc. For: Jan 03 Filed by: Watts Ryan J.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/14
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease
29.4%
1/26 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Goldman Sachs Group Inc from a "neutral" rating to a "buy" rating. 13.7%
4/1 Form 4/A Denali Therapeutics Inc. For: Feb 08 Filed by: Watts Ryan J. 8.9%
3/13 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Evercore ISI to an "outperform" rating. 7.9%
7/2 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $23.00 price target on the stock. 6.2%
10/21 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 5.7%
1/30 Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 35% [Yahoo! Finance News] 5.3%
12/3 30 Under 30 2020: Meet The Sports World’s Brightest Young Stars [Forbes] 4.6%
6/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 4.5%
11/26 Form 4 Denali Therapeutics Inc. For: Nov 22 Filed by: Schuth Alexander O. 4.5%
1/26 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Goldman Sachs Group Inc from a "neutral" rating to a "buy" rating. 13.7%
4/1 Form 4/A Denali Therapeutics Inc. For: Feb 08 Filed by: Watts Ryan J. 8.9%
3/13 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Evercore ISI to an "outperform" rating. 7.9%
7/2 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $23.00 price target on the stock. 6.2%
10/21 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 5.7%
1/30 Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 35% [Yahoo! Finance News] 5.3%
12/3 30 Under 30 2020: Meet The Sports World’s Brightest Young Stars [Forbes] 4.6%
6/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 4.5%
11/26 Form 4 Denali Therapeutics Inc. For: Nov 22 Filed by: Schuth Alexander O. 4.5%
TOP News Decliners
2/26
Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating.
-12.1%
3/30 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $21.00 price target on the stock. -11.1%
1/27 Denali Therapeutics Announces Proposed Offering of Common Stock -10.0%
1/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -9.3%
9/25 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Wedbush. They set a "neutral" rating on the stock. -9.1%
2/24 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating and a $35.00 price target on the stock. -7.2%
5/10 Form 4/A Denali Therapeutics Inc. For: Apr 01 Filed by: Ho Carole -6.7%
1/29 Form 424B5 Denali Therapeutics Inc. -6.5%
3/12 Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer -6.2%
9/13 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Nomura. They set a "buy" rating on the stock. -5.9%
3/30 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $21.00 price target on the stock. -11.1%
1/27 Denali Therapeutics Announces Proposed Offering of Common Stock -10.0%
1/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -9.3%
9/25 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Wedbush. They set a "neutral" rating on the stock. -9.1%
2/24 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating and a $35.00 price target on the stock. -7.2%
5/10 Form 4/A Denali Therapeutics Inc. For: Apr 01 Filed by: Ho Carole -6.7%
1/29 Form 424B5 Denali Therapeutics Inc. -6.5%
3/12 Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer -6.2%
9/13 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Nomura. They set a "buy" rating on the stock. -5.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: